Retifanlimab prolongs overall survival in advanced squamous cell anal cancer
Retifanlimab combined with carboplatin–paclitaxel improves overall survival versus placebo in patients with advanced squamous cell anal cancer
In the phase III POD1UM-303/InterAACT-2 study, first‑line retifanlimab plus carboplatin–paclitaxel (CP) achieved a 25% relative reduction in death risk compared with placebo + CP in 308 patients with advanced squamous cell anal cancer (SCAC). Median overall survival (OS) was 32.8 months versus 22.2 months (median follow‑up 26.3 vs 20.6 months). The benefit was consistent across most predefined subgroups.
This is the first phase‑III randomized trial demonstrating a clinically meaningful OS advantage with a PD‑1 inhibitor plus chemotherapy as standard care for advanced SCAC, a rare disease with historically poor prognosis.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Intensity‑Modulated Radiation Therapy
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- Advancements in Immunotherapy for Anal Cancer Treatment
- Background and Current Treatment of Squamous Cell Carcinoma of the Anus
- Genotyping and Cytology Co-Testing for Anal Cancer Screening: Exploratory Evaluation of Cumulative HPV Genotype Burden